PATENT CLAIM ANALYSIS

Application Number: 15924020
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-07
Patent Classification: ["514", "210210"]

Abstract:
A series of fused bicyclic heteroaromatic derivatives of formula (IA) or (IB), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.

Claim (Index 6):
The compound as claimed in  claim 4  wherein A 11  represents hydrogen or C 1-6  alkyl.

Metadata:
- Claim Count in Document: 14.0
- Percentile: 90.0
- Lexical Diversity: 1.30612
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['15318422', '15318507', '14357340', '14432842', '15513357']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7955035476234625
- 35 USC 102 Novelty (BERT): 0.560226056649962
- Combined Prediction Score: 0.7719757985261124
- Mean Citation Score: 396.094192
- Max Citation Score: 420.13782
- Similarity Product: 353.9949248622716

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test